ODTX

16.9107.80%
JH

Jason Haas

Independent Director

Mr. Jason Haas, MBA, is Chief Financial Officer of Odyssey Therapeutics, Inc. from December 2024. Mr. Haas serves as an Independent Director at Ligand Pharmaceuticals Incorporated since June 2022. He was Chief Financial Officer of Syros Pharmaceuticals, Inc. from October 2021 until November 2024. Mr. Haas served as Co-Head of Americas, Healthcare Investment Banking at Barclays plc from June 2016 to October 2021 where he executed an array of strategic transactions across the public and private markets and supported companies through equity and debt financings, mergers and acquisitions, divestitures and spin-offs. Prior to joining Barclays in 2016, he served as Head of Americas, Healthcare Investment Banking at Deutsche Bank AG. Prior to his role at Deutsche Bank, he was a Managing Director on the Healthcare Investment Banking team at Goldman Sachs & Co, where he covered life sciences companies. Mr. Haas holds an M.B.A in Finance from Columbia Business School and a B.A in International Relations and Economics from Colgate University.

Positions